Clinical Trial · NCT07109440

The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases

Overview

FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery

Sponsor

Jules Bordet Institute

Phase

N/A

Contacts

Loubna Taraji, MS (CONTACT)

loubna.taraji@hubruxelles.be

02.541.37.81

ClinicalTrials.gov

NCT07109440

Eligibility

Inclusion

Scheduled for liver metastasis resection
ECOG Performance status ≤2.
Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET/CT)
Naïve for treatment or after neoadjuvant chemotherapy

Exclusion

Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Pregnant and lactating women
Non-resectable liver metastases